1476-0584

Expert Review of Vaccines

Informa UK (Taylor & Francis)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1926 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1926 DOIs
2

Attach ORCID iDs across 1926 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact1926 DOIs
3

Add license metadata to 1907 records

License metadata tells indexers and readers how each article may be reused.

High impact1907 DOIs

DOIs for this ISSN

Showing the top 5 of 1904 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Virus-like particles in vaccine development (10.1586/erv.10.115)
Abstract ORCID License
215.89 755
2 Vaccine hesitancy, vaccine refusal and the anti-vaccine move… (10.1586/14760584.2015.964212)
Abstract ORCID License
215.76 752
3 CpG DNA as a vaccine adjuvant (10.1586/erv.10.174)
Abstract ORCID License
214.88 732
4 Vaccines for fish in aquaculture (10.1586/14760584.4.1.89)
Abstract ORCID License
209.17 614
5 The fundamental link between pneumococcal carriage and disea… (10.1586/erv.12.53)
Abstract ORCID License
208.14 595
6 Nano-microparticles as immune adjuvants: correlating particl… (10.1586/erv.10.89)
Abstract ORCID License
201.96 492
7 Poultry coccidiosis: recent advancements in control measures… (10.1586/14760584.5.1.143)
Abstract ORCID License
200.89 476
8 GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achi… (10.1586/14760584.6.5.723)
Abstract ORCID License
196.04 410
9 Development and evaluation of AS03, an Adjuvant System conta… (10.1586/erv.11.192)
Abstract ORCID License
188.29 323
10 Recent clinical experience with vaccines using MPL- and QS-2… (10.1586/erv.11.29)
Abstract ORCID License
184.79 290
11 Virus-like particles: flexible platforms for vaccine develop… (10.1586/14760584.6.3.381)
Abstract ORCID License
184.57 288
12 The history of MF59 <sup>®</sup> adj… (10.1586/erv.12.140)
Abstract ORCID License
184.45 287
13 Technologies for enhanced efficacy of DNA vaccines (10.1586/erv.11.188)
Abstract ORCID License
182.95 274
14 Montanide ISA 720 and 51: a new generation of water in oil e… (10.1586/14760584.1.1.111)
Abstract ORCID License
181.62 263
15 Vero cell platform in vaccine production: moving towards cel… (10.1586/erv.09.19)
Abstract ORCID License
180.62 255
16 The use of Toll-like receptor 7/8 agonists as vaccine adjuva… (10.1586/14760584.2013.811208)
Abstract ORCID License
179.32 245
17 MF59 is a safe and potent vaccine adjuvant that enhances pro… (10.1586/14760584.6.5.699)
Abstract ORCID License
179.19 244
18 Relationship between physical and chemical properties of alu… (10.1586/14760584.6.5.685)
Abstract ORCID License
178.92 242
19 Nanoparticles and microparticles as vaccine-delivery systems (10.1586/14760584.6.5.797)
Abstract ORCID License
176.41 224
20 Intradermal, epidermal and transcutaneous vaccination: from… (10.1586/14760584.7.8.1201)
Abstract ORCID License
176.27 223
21 Effect of vaccine administration modality on immunogenicity… (10.1586/14760584.2015.1081067)
Abstract ORCID License
175.68 219
22 mRNA transcript therapy (10.1586/14760584.2015.973859)
Abstract ORCID License
174.17 209
23 Enhancement of antigen-specific immunity via the TLR4 ligand… (10.1586/14760584.2.2.219)
Abstract ORCID License
173.54 205
24 Vaccine adjuvant uses of poly-IC and derivatives (10.1586/14760584.2015.966085)
Abstract ORCID License
173.38 204
25 Opportunities and challenges of developing thermostable vacc… (10.1586/erv.09.20)
Abstract ORCID License
173.22 203
26 Chikungunya virus and prospects for a vaccine (10.1586/erv.12.84)
Abstract ORCID License
173.22 203
27 Epaxal<sup>®</sup>: a virosomal vaccine to prevent hepatitis… (10.1586/14760584.7.8.1141)
Abstract ORCID License
172.90 201
28 Vaccination against foot-and-mouth disease virus: strategies… (10.1586/14760584.8.3.347)
Abstract ORCID License
171.59 193
29 <i>Salmonella</i>vaccines in poultry: past, present and futu… (10.1586/erv.12.138)
Abstract ORCID License
171.42 192
30 Natural and synthetic saponin adjuvant QS-21 for vaccines ag… (10.1586/erv.11.18)
Abstract ORCID License
171.25 191
31 Lipid-based mRNA vaccine delivery systems (10.1586/14760584.2015.986104)
Abstract ORCID License
170.56 187
32 EV71 vaccine, a new tool to control outbreaks of hand, foot… (10.1586/14760584.2016.1138862)
Abstract ORCID License
169.68 182
33 Yellow fever vaccine (10.1586/14760584.4.4.553)
Abstract ORCID License
169.15 179
34 Meningococcal vaccines and herd immunity: lessons learned fr… (10.1586/erv.09.48)
Abstract ORCID License
168.78 177
35 Advances in the design and delivery of peptide subunit vacci… (10.1586/erv.09.160)
Abstract ORCID License
168.60 176
36 Potential of the test-negative design for measuring influenz… (10.1586/14760584.2014.966695)
Abstract ORCID License
168.41 175
37 Microparticles as vaccine adjuvants and delivery systems (10.1586/14760584.2.2.269)
Abstract ORCID License
168.23 174
38 MF59-adjuvanted vaccines: increased immunogenicity with an o… (10.1586/14760584.2.2.197)
Abstract ORCID License
168.04 173
39 Universal M2 ectodomain-based influenza A vaccines: preclini… (10.1586/erv.09.6)
Abstract ORCID License
168.04 173
40 Trends in vaccine adjuvants (10.1586/erv.11.21)
Abstract ORCID License
168.04 173
41 The evolving history of influenza viruses and influenza vacc… (10.1586/14760584.2013.824709)
Abstract ORCID License
167.85 172
42 Inactivated virus vaccines from chemistry to prophylaxis: me… (10.1586/erv.12.38)
Abstract ORCID License
167.47 170
43 New hepatitis B vaccine formulated with an improved adjuvant… (10.1586/14760584.6.2.133)
Abstract ORCID License
166.51 165
44 ELISpot for measuring human immune responses to vaccines (10.1586/erv.10.169)
Abstract ORCID License
166.31 164
45 Preventing urinary tract infection: progress toward an effec… (10.1586/erv.12.36)
Abstract ORCID License
166.11 163
46 SARS vaccines: where are we? (10.1586/erv.09.43)
Abstract ORCID License
165.10 158
47 Recent progress concerning CpG DNA and its use as a vaccine… (10.1586/14760584.2014.863715)
Abstract ORCID License
164.90 157
48 Cationic liposomes as vaccine adjuvants (10.1586/erv.11.17)
Abstract ORCID License
164.90 157
49 Development of TV003/TV005, a single dose, highly immunogeni… (10.1586/14760584.2016.1115727)
Abstract ORCID License
164.69 156
50 ISCOM technology-based Matrix M™ adjuvant: success in future… (10.1586/erv.11.25)
Abstract ORCID License
164.69 156